Lidogrell is a dual-acting agent that can be used to prevent systemic thromboembolism and as an adjunct to thrombolytic therapy in acute myocardial infarction.
Antibacterial Agent 47 demonstrates potent antibacterial activity as an adjunct therapy to parenteral antibiotic Ceftazidime. By effectively reducing the minimum inhibitory concentration (MIC) of Ceftazidime, Antibacterial Agent 47 acts as a highly promising antimicrobial agent, thereby enhancing the overall efficacy of the treatment.